Mural Oncology (Mural Oncology) Debt-to-Equity : 0.06 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Debt-to-Equity?

Mural Oncology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6.16 Mil. Mural Oncology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $7.33 Mil. Mural Oncology's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $234.93 Mil. Mural Oncology's debt to equity for the quarter that ended in Mar. 2024 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Mural Oncology's Debt-to-Equity or its related term are showing as below:

MURA' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.39 Med: -0.42 Max: 0.06
Current: 0.06

During the past 3 years, the highest Debt-to-Equity Ratio of Mural Oncology was 0.06. The lowest was -2.39. And the median was -0.42.

MURA's Debt-to-Equity is ranked better than
69.62% of 1060 companies
in the Biotechnology industry
Industry Median: 0.14 vs MURA: 0.06

Mural Oncology Debt-to-Equity Historical Data

The historical data trend for Mural Oncology's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology Debt-to-Equity Chart

Mural Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Equity

-1.42

-0.90

0.06

Mural Oncology Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial				N/A	0.06	-2.39	0.06	0.06

Competitive Comparison of Mural Oncology's Debt-to-Equity

For the Biotechnology subindustry, Mural Oncology's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mural Oncology's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mural Oncology's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Mural Oncology's Debt-to-Equity falls into.

Mural Oncology Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Mural Oncology's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.098	+	8.911)	/	263.817
	=	0.06

Mural Oncology's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.156	+	7.33)	/	234.927
	=	0.06

Mural Oncology (NAS:MURA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Mural Oncology Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Mural Oncology's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mural Oncology (Mural Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Earlsfort Terrace, Dublin, IRL, D02 T380

Website

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging their core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The Company operates as one business segment, which is the business of developing medicines designed to address unmet medical needs of patients in the area of oncology.

Mural Oncology (Mural Oncology) Headlines

From GuruFocus

Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

By Marketwired • 04-24-2024